Weijin Huang

2006–2025 年に発表

107
論文数
20,901
被引用数
47
h 指数
95
i10 指数

被引用数

Weijin Huang の年別被引用数2002 年: 被引用 2 件2004 年: 被引用 2 件2005 年: 被引用 1 件2006 年: 被引用 1 件2008 年: 被引用 2 件2010 年: 被引用 1 件2011 年: 被引用 1 件2012 年: 被引用 1 件2014 年: 被引用 3 件2015 年: 被引用 5 件2016 年: 被引用 11 件2017 年: 被引用 13 件2018 年: 被引用 12 件2019 年: 被引用 44 件2020 年: 被引用 686 件2021 年: 被引用 2,083 件2022 年: 被引用 2,241 件2023 年: 被引用 1,019 件2024 年: 被引用 1,095 件2025 年: 被引用 428 件2026 年: 被引用 8 件2003 年は被引用が無いため表示していません2007 年は被引用が無いため表示していません2009 年は被引用が無いため表示していません2013 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 2,125 件、この内訳の 22.6%アメリカ合衆国: 引用元論文 1,977 件、この内訳の 21%イギリス: 引用元論文 524 件、この内訳の 5.6%ドイツ: 引用元論文 326 件、この内訳の 3.5%インド: 引用元論文 286 件、この内訳の 3%カナダ: 引用元論文 266 件、この内訳の 2.8%フランス: 引用元論文 236 件、この内訳の 2.5%イタリア: 引用元論文 225 件、この内訳の 2.4%日本: 引用元論文 196 件、この内訳の 2.1%オーストラリア: 引用元論文 186 件、この内訳の 2%香港: 引用元論文 177 件、この内訳の 1.9%韓国: 引用元論文 172 件、この内訳の 1.8%
0%22.6%その他 28.8%

分野

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology13.2%
  • Immunology and Microbiology3.8%
  • Engineering1.2%
  • Agricultural and Biological Sciences0.8%
  • Computer Science0.8%
  • その他3.2%

トピック

  • SARS-CoV-2 and COVID-19 Research24%
  • COVID-19 Clinical Research Studies11.1%
  • SARS-CoV-2 detection and testing5%
  • vaccines and immunoinformatics approaches3.9%
  • Animal Virus Infections Studies3.8%
  • Viral gastroenteritis research and epidemiology3.5%
  • その他48.7%

共著者

全論文

検索で開く
  1. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Youchun Wang, Xiaoliang Sunney Xie - Nature 2021 被引用: 2,131

  2. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sijie Yang, Xuetao Song, Yangyang Chai, Yansong Shi, Yansong Shi, Linlin Zheng, Zhiqiang Li, Qingqing Gu, Fei Shao, Weijin Huang, Ronghua Jin, Zhongyang Shen, Xiangxi Wang, Youchun Wang, Xiangxi Wang, Junyu Xiao, Xiaoliang Sunney Xie - Nature 2022 被引用: 1,454

  3. Circular RNA vaccines against SARS-CoV-2 and emerging variants

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xiaoliang Sunney Xie, Wensheng Wei - Cell 2022 被引用: 625

  4. A Thermostable mRNA Vaccine against COVID-19

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cheng‐Feng Qin - Cell 2020 被引用: 697

  5. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2020 被引用: 1,499

  6. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

    著者: , , , , , , , , , , , , , , , , , , , - Cell 2020 被引用: 1,643

  7. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 被引用: 133

  8. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Guanpeng Wang, Pin Yü, Yajin Qu, Li Yang, Hongxin Deng, Aiping Tong, Jiong Li, Zhenling Wang, Jinliang Yang, Guobo Shen, Zhiwei Zhao, Yuhua Li, Jingwen Luo, Hongqi Liu, Wenhai Yu, Mengli Yang, Jingwen Xu, Junbin Wang, Haiyan Li, Haixuan Wang, Dexuan Kuang, Panpan Lin, Zhengtao Hu, Wei Guo, Wei Cheng, Yanlin He, Xiangrong Song, Chong Chen, Zhihong Xue, Shaohua Yao, Lu Chen, Xuelei Ma, Siyuan Chen, Maling Gou, Weijin Huang, Youchun Wang, Changfa Fan, Zhixin Tian, Ming Shi, Fu‐Sheng Wang, Lunzhi Dai, Min Wu, Gen Li, Guangyu Wang, Yong Peng, Zhiyong Qian, Canhua Huang, Johnson Yiu‐Nam Lau, Zhenglin Yang, Yuquan Wei, Xiaobo Cen, Xiaozhong Peng, Chuan Qin, Kang Zhang, Guangwen Lu, Xiawei Wei - Nature 2020 被引用: 849

  9. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

    著者: , , , , , , , , , , , , , , , , , - Nature Protocols 2020 被引用: 469

  10. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus

    著者: , , , , , , , , , , , , , , , - Signal Transduction and Targeted Therapy 2023 被引用: 108

  11. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Host & Microbe 2020 被引用: 657

  12. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

    著者: , , , , , , , , , , , , , , , , , - Emerging Microbes & Infections 2020 被引用: 802

  13. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Qiu-Fen Zhang, Guang Sun, Fengcai Zhu, Shaowei Li, Yimin Li, Huirong Pan, Jun Zhang, You‐Lin Qiao, Ningshao Xia - The Lancet Infectious Diseases 2022 被引用: 89

  14. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wanshen Guo, Xiaoming Yang, Xiaoming Yang, Xiaoming Yang - The Lancet Infectious Diseases 2020 被引用: 1,210

  15. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 146

  16. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Signal Transduction and Targeted Therapy 2021 被引用: 124

  17. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Youchun Wang, Xiaoliang Sunney Xie, Xiao‐Dong Su, Junyu Xiao, Chuan Qin - Cell 2020 被引用: 289

  18. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cell Research 2022 被引用: 109

  19. Metal-phenolic nanocatalyst rewires metabolic vulnerability for catalytically amplified ferroptosis

    著者: , , , , , , , , , , , - Chemical Engineering Journal 2024 被引用: 45

  20. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

    著者: , , , , , , , , , , - Emerging Microbes & Infections 2021 被引用: 396

  21. Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Cell Discovery 2022 被引用: 104

  22. Current status on the development of pseudoviruses for enveloped viruses

    著者: , , , , - Reviews in Medical Virology 2017 被引用: 175

  23. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ronghua Jin, Yingmin Ma, Cheng‐Feng Qin, Youchun Wang, Yingmei Feng, Junyu Xiao, Xiaoliang Sunney Xie - Cell Research 2021 被引用: 170

  24. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yi‐Ping Li, Youchun Wang, Wenpei Liu, Xiaowang Qu - Nature Microbiology 2020 被引用: 158